Advanced searches left 3/3

Metastatic Breast Cancer Trial - Europe PMC

Summarized by Plex Scholar
Last Updated: 03 May 2022

* If you want to update the article please login/register

Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.

Overview Anticancer treatment regimens have been reported as having unpleasant side-effects. With fixed cycles of first-line induction chemotherapy with weekly paclitaxel-positive, HER2-negative advanced or metastatic breast cancer, we aimed to investigate the benefit of switching maintenance endocrine therapy plus bevacizumab. Patients with no response, partial response, or stable disease following induction therapy were then randomly assigned in the randomization enrolment system to either continue weekly paclitaxel plus bevacizumab or switch to maintenance endocrine therapy plus bevacizumab. Patients with disease initiation or maintenance endocrine therapy plus bevacizumab may have received weekly paclitaxel plus bevacizumab reinduction if they had disease progression with maintenance endocrine therapy plus bevacizumab. Our Results Between Jan 1, 2014 and Dec 31, 2015, we had 160 patients who began weekly paclitaxel plus bevacizumab induction therapy. Patients were randomly assigned to endocrine therapy plus bevacizumab or weekly paclitaxel plus bevacizumab. 32 patients were recalled on weekly paclitaxel plus bevacizumab, out of 61 patients in the switch maintenance endocrine therapy plus bevacizumab group, with 32 others being reactivated on weekly paclitaxel plus bevacizumab. TFS was much longer in the endocrine therapy plus bevacizumab group than in the weekly paclitaxel plus bevacizumab group, with a median follow-up of 21 months. Interpretation Switching from maintenance endocrine therapy plus bevacizumab with the possibility of weekly paclitaxel reinduction if necessary is an innovative alternative to continuing weekly paclitaxel plus bevacizumab in patients with ER-positive, HER2-negative advanced or metastatic breast cancer patients who have responded to induction therapy.

Source link: https://europepmc.org/article/MED/35405087


The benefits and acceptability of virtual reality interventions for women with metastatic breast cancer in their homes; a pilot randomised trial.

Background Women with metastatic breast cancer report debilitating physical and psychological signs, including exhaustion, depression, and pain, which greatly impact their quality of life. Immersive virtual reality has been suggested as an adjunctive pain therapy for patients with cancer, and studies show it can also reduce anxiety and depression. This pilot study was conducted to see if VR should be pursued as a safe and appropriate adjunctive therapy to reduce physical and psychological symptoms in women with MBC. Methods We carried out a pilot study investigating the acceptability and efficacy of VR interventions with MBC patients to increase quality of life and create lasting decreases in fatigue, pain, depression, anxiety, and stress. To determine the effect of immersive VR on all outcome measures, Linear mixed models with fixed effects and random effects were used.

Source link: https://europepmc.org/article/MED/35366823


Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.

Despite the widespread prognostic stratification of circulating tumor cells enumeration in metastatic breast cancer, new clinical trials do not include a baseline CTC in their study. This study was designed to produce a classifier for CTCs prognostic simulation in existing datasets for hypothesis generation in patients with MBC. On a pooled database of 2436 individual MBC patients from the European Pooled Analysis Consortium and the MD Anderson Cancer Center, researchers were trained to identify patients with CTCs > 5/7 mL blood samples, with a K-nearest neighbor machine learning algorithm. Patients with liver metastases classified as Simulatedaggressive had a significantly reduced chance of surviving, but patients with liver metastases classified as Simulatedindolent had a significantly improved prognosis. Simulatedaggressive patients had a statistically significant difference favoring CT over ET for those patients, despite a statistically significant difference.

Source link: https://europepmc.org/article/MED/35278078


Phase II Trial of Metronomic Capecitabine and Cyclophosphamide with Lapatinib and Trastuzumab in Patients with HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab- Based Regimen

Background: Breast cancer is the most common cancer and the second most common cause of cancer deaths in women. Around 25% of all breast cancers have overexpression of Human Epidermal growth factor 2, which is correlated with earlier recurrence and shorter overall survival. A new model in cancer therapy involves frequent low doses of chemotherapeutic agents, which are administered at regular intervals. In HER2-positive patients with MBC, we suggested a regimen with metronomic chemotherapy with dual HER2 inhibition in HER2-positive patients with MBC. Female patients aged 18 years of age and older who had histologically confirmed HER2-positive metastatic breast cancer with prior trastuzumab use in the adjuvant or metastatic setting were eligible. The proposed regimen of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab seems to be safe in patients with HER2 positive MBC but not to the same as other standard therapies.

Source link: https://europepmc.org/article/PPR/PPR465811


Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.

Introduction The combination of a CDK4/6 inhibitor and an aromatase inhibitor has recently become the gold standard for AI-based therapy of oestrogen receptor-positive advanced breast cancer patients with oestrogen receptor-positive HER2-negative breast cancer. When assessing global safety, we want to establish the clinical sensitivity of periodic testing for emerging or increasing ESR1 mutations in ctDNA to ignite an early change from AI plus palbociclib to fullvestrant plus palbociclib treatment. Methods PADA-1 is a randomised, open-label, multicentric phase III trial conducted in patients receiving AI and palbociclib as the first line therapy for metastatic ER+HER2- breast cancer. Patients will be tested for circulating blood ESR1 mutation detection at regular intervals. Patients for whom a rising circulating ESR1 mutation is present without tumour progression will be randomised between Arm A and Arm B: no change in therapy; and Arm B: palbociclib in combination with fulvestrant, a selective ER down regulator.

Source link: https://europepmc.org/article/MED/35241469

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions